Hematopoietic Cell Patents (Class 424/173.1)
-
Publication number: 20140294861Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.Type: ApplicationFiled: February 17, 2014Publication date: October 2, 2014Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
-
Publication number: 20140294825Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.Type: ApplicationFiled: April 3, 2014Publication date: October 2, 2014Applicant: JN Biosciences LLCInventors: J. Yun Tso, Naoya Tsurushita
-
Publication number: 20140294807Abstract: The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Another aspect of the invention is a kit comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type I anti-CD20 antibody and a type II anti-CD20 antibody.Type: ApplicationFiled: October 30, 2013Publication date: October 2, 2014Applicant: ROCHE GLYCART AGInventors: THOMAS FRIESS, CHRISTIAN KLEIN, PABLO UMANA
-
Patent number: 8846045Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.Type: GrantFiled: June 18, 2013Date of Patent: September 30, 2014Assignee: Novo Nordisk A/SInventors: Kristian Kjaergaard, Soeren Lund
-
Publication number: 20140286933Abstract: The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis.Type: ApplicationFiled: March 26, 2013Publication date: September 25, 2014Applicant: SanofiInventor: Sanofi
-
Patent number: 8840889Abstract: Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. In another aspect, the therapeutic agents modulate the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. The therapeutic agents can be used in the prevention, treatment and/or management of diseases in which it might be useful to modulate one or more immune functions (e.g., cancer, infectious disease, autoimmune disease, and transplantation rejection). In another aspect, presented herein are methods for identifying receptor-ligand interactions.Type: GrantFiled: August 13, 2010Date of Patent: September 23, 2014Assignee: The Johns Hopkins UniversityInventor: Lieping Chen
-
Patent number: 8840897Abstract: A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA1a within 72 hours after delivery in the first non-compatible pregnancy.Type: GrantFiled: December 29, 2006Date of Patent: September 23, 2014Assignee: Prophylix Pharma ASInventors: Bjorn Skogen, Anne Husse-Bekk, Mette Kjaer Killie, Jens Kjeldsen-Kragh
-
Publication number: 20140271682Abstract: The invention generally relates to human biology discoveries and therapeutic and diagnostic compositions and methods based thereon. More particularly, the invention relates to human homeobox gene VentX and its control of macrophage terminal differentiation and activation, and related therapeutic and diagnostic compositions and methods of use, in particular in connection with inflammatory diseases.Type: ApplicationFiled: June 10, 2012Publication date: September 18, 2014Inventor: Zhenglun ZHU
-
Publication number: 20140271639Abstract: The present invention provides methods of treating a mammal diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the mammal a compound or composition which modulates a target, such as Cofilin-1 and/or Plexin C1. The method of the invention also comprises administering to the mammal a compound or composition which inhibits a lymphocyte that expresses Sema 7a.Type: ApplicationFiled: October 4, 2012Publication date: September 18, 2014Inventor: Erica Herzog
-
Patent number: 8828396Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.Type: GrantFiled: November 14, 2011Date of Patent: September 9, 2014Assignee: Novartis AGInventors: Christoph Heusser, James Rush, Karen Vincent
-
Patent number: 8828397Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: September 14, 2012Date of Patent: September 9, 2014Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Publication number: 20140248289Abstract: Methods and compositions for the treatment of respiratory conditions are provided. Aspects of the subject methods include administering to the subject a composition comprising an inhibitor of NKG2D-mediated activation of leukocytes. Also provided are compositions suitable for use in the subject methods, as well as pharmaceutical preparations thereof.Type: ApplicationFiled: August 24, 2012Publication date: September 4, 2014Applicants: UNIVERSITY OF CINCINNATI, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: University of Cincinnati
-
Publication number: 20140242094Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.Type: ApplicationFiled: February 20, 2014Publication date: August 28, 2014Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Vijay K. Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
-
Patent number: 8815246Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: GrantFiled: September 14, 2012Date of Patent: August 26, 2014Assignees: Dyax Corp., Syntonix Pharmaceuticals, Inc.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Patent number: 8815242Abstract: The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produced in a transgenic avian. The antibody molecules have a heavy chain and a light chain whose amino acid sequences set forth in SEQ ID NOs: 4 and 5 and exhibit an increased level of cytotoxicity as compared to anti-CD20 antibody molecules produced in CHO cells.Type: GrantFiled: May 27, 2010Date of Patent: August 26, 2014Assignee: Synageva BioPharma Corp.Inventor: Alex J. Harvey
-
Publication number: 20140234344Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.Type: ApplicationFiled: January 27, 2014Publication date: August 21, 2014Applicant: Baylor Research InstituteInventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
-
Publication number: 20140234333Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases are therapeutically useful.Type: ApplicationFiled: April 8, 2014Publication date: August 21, 2014Applicant: Rigel Pharmaceuticals, Inc.Inventors: Hui Li, Ankush Argade, Sambaiah Thota, David Carroll, Arvinder Sran, Robin Cooper, Rajinder Singh, Kin Tso, Somasekhar Bhamidipati
-
Patent number: 8808701Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.Type: GrantFiled: December 19, 2012Date of Patent: August 19, 2014Assignee: G2 Inflammation Pty LtdInventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
-
Publication number: 20140220042Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C?mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C?mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of C?mX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of C?mX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.Type: ApplicationFiled: April 16, 2014Publication date: August 7, 2014Applicant: Academia SinicaInventors: Tse Wen Chang, Jiun-Bo Chen, Pheidias C. Wu, Alfur F. Hung
-
Publication number: 20140220029Abstract: Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound.Type: ApplicationFiled: April 10, 2014Publication date: August 7, 2014Applicant: Novo Nordisk A/SInventors: Birgitte Koch Michelsen, Jeppe Sturis
-
Publication number: 20140212422Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.Type: ApplicationFiled: March 27, 2014Publication date: July 31, 2014Applicants: Ono Pharmaceutical Co., Ltd.Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
-
Publication number: 20140212425Abstract: Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, the antibodies induce trogocytosis of B-cell antigens, such as CD19, CD20, CD21, CD22, CD79b, CD44, CD62L, or ?7-integrin. Trogocytosis may play a significant role in determining antibody efficacy, disease responsiveness and prognosis of therapeutic intervention and trogocytosis-dependent responses may be monitored by measuring the levels of trogocytosis of one or more B-cell surface antigens induced by the bispecific antibody.Type: ApplicationFiled: April 2, 2014Publication date: July 31, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen, Edmund A. Rossi
-
Publication number: 20140205538Abstract: The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family. Also provided are means and methods for overcoming host immunological tolerance to death receptors. The vaccines are useful against cancer cells and other death receptor bearing target cells within the host, and can be used in both therapeutic and prophylactic settings. The vaccines are also useful for diagnostic testing of the immunocompetence of a host.Type: ApplicationFiled: January 15, 2014Publication date: July 24, 2014Applicant: Wayne State UniversityInventors: Wei-Zen Wei, Gen Sheng Wu, Marie P. Piechocki, Richard F. Jones
-
Patent number: 8784823Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.Type: GrantFiled: October 22, 2012Date of Patent: July 22, 2014Assignees: Biogen Idec MA Inc., UCB Biopharma SPRLInventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson
-
Publication number: 20140199238Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).Type: ApplicationFiled: March 19, 2014Publication date: July 17, 2014Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
-
Patent number: 8778345Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: GrantFiled: April 27, 2012Date of Patent: July 15, 2014Assignee: Apexigen, Inc.Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Publication number: 20140186373Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.Type: ApplicationFiled: December 8, 2011Publication date: July 3, 2014Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
-
Publication number: 20140178294Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.Type: ApplicationFiled: December 18, 2013Publication date: June 26, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20140178370Abstract: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.Type: ApplicationFiled: December 30, 2013Publication date: June 26, 2014Applicants: Emory University, President and Fellows of Harvard College, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Inc.Inventors: Gordon Freeman, Arlene Sharpe, David M. Dorfman, Rafi Ahmed, Daniel Barber, E. John Wherry
-
Publication number: 20140170168Abstract: Provided are isolated high affinity entities which comprise an antigen binding domain which specifically binds a soluble T-cell receptor ligand comprising a two-domain beta1-alpha1 of a major histocompatibility complex (MHC) class II, wherein said antigen binding domain does not bind a complex comprising a four-domain alpha1-beta1/alpha2-beta2 MHC class II. Also provided are methods and kits using same for detecting and sequestering soluble two-domain T cell receptor ligands in a sample.Type: ApplicationFiled: October 26, 2011Publication date: June 19, 2014Inventors: Yoram Reiter, Rony Dahan, Arthur A. Vandenbark
-
Publication number: 20140170169Abstract: A method can include administering a donor-specific human leukocyte antigen antibody to a tissue transplant recipient where the antibody is an immunoglobulin G subclass 4 antibody (G4). Various other examples of devices, assemblies, systems, methods, etc., are also disclosed.Type: ApplicationFiled: December 19, 2013Publication date: June 19, 2014Inventors: James Cicciarelli, Nori Kasahara, Nathan Lemp
-
Patent number: 8753629Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: GrantFiled: June 14, 2013Date of Patent: June 17, 2014Assignee: Xencor, Inc.Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Publication number: 20140161818Abstract: The present invention relates to antigen-specific immune regulatory response. Methods for detecting an antigen-specific immune regulatory response, methods for selecting candidate vaccine recipients, and methods for improved vaccination strategies are presented.Type: ApplicationFiled: December 6, 2013Publication date: June 12, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Douglas G. McNeel, William J. Burlingham
-
Publication number: 20140161805Abstract: Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.Type: ApplicationFiled: November 1, 2013Publication date: June 12, 2014Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Catriona Helen M. Jamieson, Irving L. Weissman, Siddhartha Jaiswal, Ravindra Majeti
-
Publication number: 20140161824Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.Type: ApplicationFiled: August 8, 2012Publication date: June 12, 2014Inventors: Alexander Shneider, Franco Venanzi, Michael Sherman, Victor Shifrin
-
Patent number: 8741294Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C?mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C?mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of C?mX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of C?mX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.Type: GrantFiled: May 7, 2013Date of Patent: June 3, 2014Assignee: Academia SinicaInventors: Tsewen Chang, Jiun-Bo Chen, Pheidias C. Wu, Alfur F. Hung
-
Publication number: 20140147451Abstract: A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL.Type: ApplicationFiled: February 5, 2014Publication date: May 29, 2014Applicant: Yeda Research and Development Co. Ltd.Inventors: Idit SHACHAR, Inbal Binsky, Mirko Sobotta
-
Publication number: 20140147413Abstract: The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.Type: ApplicationFiled: February 28, 2012Publication date: May 29, 2014Inventors: Dong Feng Chen, Jianzhu Chen, Huihui Chen
-
Publication number: 20140147382Abstract: The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed.Type: ApplicationFiled: January 30, 2014Publication date: May 29, 2014Applicant: IMMUNOMEDICS, INC.Inventors: David M. GOLDENBERG, Hans HANSEN
-
Publication number: 20140140988Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a MDM2 inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a MDM2 inhibitor.Type: ApplicationFiled: June 13, 2013Publication date: May 22, 2014Applicant: Roche Glycart AGInventors: ERIC ELDERING, FRANK HERTING, CHRISTIAN KLEIN, MARINUS H.J. VAN OERS
-
Publication number: 20140141020Abstract: This document provides methods and materials related to anti-CD3 therapies. For example, anti-CD3?? antibody preparations as well as methods and materials for using anti-CD3?? antibody preparations to reduce a T cell-mediated immune response within a mammal are provided.Type: ApplicationFiled: June 5, 2012Publication date: May 22, 2014Applicant: Mayo Foundation for Medical Education and ResearchInventors: Diana Gil Pages, Adam G. Schrum
-
Patent number: 8728481Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.Type: GrantFiled: July 17, 2012Date of Patent: May 20, 2014Assignee: Baylor Research InstituteInventors: Jacques F. Banchereau, SangKOn Oh, Gerard Zurawski, Sandra Zurawski, Dapeng Li
-
Publication number: 20140134190Abstract: Methods of determining cancer progression or cancer relapse in a subject at risk for cancer progression or cancer relapse, the methods comprising: obtaining a sample from said subject; measuring the level of VEGFR1+ hematopoietic progenitor cells (HPCs) and/or VEGFR2+ endothelial progenitor cells (EPCs) in said sample; and taking additional samples and conducting additional measurements of HPCs and/or EPCs at one or more later time points. From the measurements, it can be determined whether there is a surge in the level of HPCs and/or EPCs in at least one later measurement, relative to an earlier measurement. A surge in the level of HPCs and/or EPCs indicates increased risk of progression or relapse of said subject's cancer.Type: ApplicationFiled: February 24, 2012Publication date: May 15, 2014Applicant: Cornell UniversityInventors: Linda Vahdat, Shahin Rafii, Rakhi Naik, Maureen Lane, Vivek Mittal
-
Publication number: 20140127236Abstract: The present invention relates to novel humanised antibodies against human CD52 and their use in methods of treating or preventing human diseases.Type: ApplicationFiled: June 1, 2012Publication date: May 8, 2014Applicant: ANTITOPE LIMITEDInventors: Timothy David JONES, Robert George Edward Holgate, Francis Joseph Carr
-
Publication number: 20140127197Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.Type: ApplicationFiled: February 6, 2013Publication date: May 8, 2014Applicant: GENENTECH, INC.Inventor: GENENTECH, INC.
-
Patent number: 8715619Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.Type: GrantFiled: February 11, 2013Date of Patent: May 6, 2014Assignee: Cellerant Therapeutics, Inc.Inventor: Holger Karsunky
-
Publication number: 20140120082Abstract: The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.Type: ApplicationFiled: March 12, 2013Publication date: May 1, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: The Regents of the University of California
-
Publication number: 20140120115Abstract: The present disclosure relates to antigen-binding moieties that specifically bind to MIF and D-DT and compositions and methods of use thereof.Type: ApplicationFiled: July 13, 2012Publication date: May 1, 2014Applicant: MorphoSys AGInventors: Swen Zierow, Juergen Klattig
-
Publication number: 20140120086Abstract: The present invention provides a method for preparation of a high concentration liquid formulation (HCLF) of an antibody or a fragment thereof. The present invention also relates to a method for stabilizing an anti-CD20 antibody or a fragment thereof in a liquid pharmaceutical formulation. Furthermore, the present invention relates to a liquid pharmaceutical formulation of a veltuzumab antibody or a fragment thereof comprising at least 155 mg/mL of a veltuzumab antibody or a fragment thereof.Type: ApplicationFiled: October 31, 2013Publication date: May 1, 2014Applicant: Takeda GmbHInventors: Markus RAST, Peter SKUFCA, Wolfram STEINHILBER, Gerhard BECKER, Jurgen VOLZ, Wolfgang ISE
-
Publication number: 20140105887Abstract: Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling.Type: ApplicationFiled: August 9, 2013Publication date: April 17, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Alissa A. Chackerian, Robert A. Kastelein